[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Qualia Life Sciences\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":265},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,10,0,[8,51,79,102,124,149,174,197,222,244],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100642226","the-impact-of-qualia-vitamin-c-on-individuals-with-suboptimal-and-adequate-vitamin-c-levels-100642226",false,"NCT07652346","The Impact of Qualia Vitamin C+ on Individuals With Suboptimal and Adequate Vitamin C Levels","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study.\n* Agree to provide a valid cell phone number and are willing to receive communications through text.\n* Can read and write English.\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Healthy male and female participants aged 25 to 75 years old.\n* Willing to go to an Ulta Labs Patient Service Center location for a Blood Vitamin C Test (baseline and Day 29) and located within a convenient distance of participating locations. The services offered by Ulta Lab Tests are available only in the United States and not to residents of the states of New Jersey, New York, and Rhode Island.\n* Willing to avoid starting new or stopping any existing dietary supplements throughout the study.\n* Willing to maintain a consistent diet throughout the study.\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant or start breastfeeding during the trial.\n* Known food intolerances\u002Fallergy to any ingredients in the product.\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer.\n* Having had a significant cardiovascular event in the past 6 months.\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines.\n* On immunosuppressive therapy.\n* Adults lacking capacity to consent.",true,"ALL","25 Years","75 Years",{"count":20,"type":21},152,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is a randomized, double-blind, placebo-controlled, parallel-group, study evaluating the effect of a Qualia Vitamin C+ formulation on Whole Blood Vitamin C levels in the blood of healthy adults aged 25 years or older that have suboptimal vitamin C blood levels (i.e., 0.4 - 0.9 mg\u002FdL) and those with adequate vitamin C blood levels (≥0.9 mg\u002FdL). Approximately 152 (76 in the suboptimal stratum and 76 in the adequate stratum) participants will be randomized to one of two study arms: Qualia Vitamin C+ or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in blood vitamin C levels in the suboptimal stratum, assessed via lab blood collection at baseline and study completion. Secondary endpoints include the change in blood vitamin C levels, assessed via lab blood collection at baseline and study completion in the entire group, questionnaires measuring health-related Quality of Life and fatigue (RAND-36 and the FACIT-Fatigue Scale), the Single-item Assessment of Immune Fitness, evaluation of safety and tolerability, and an Overall Experience Questionnaire. Further, a sub-group analysis of fatigued participants meeting at least mild to moderate fatigue as measured by the FACIT-Fatigue will be a secondary objective. The NCI Fruits and Vegetable Screener - All-Day Screener will also be used to assess intake at baseline and study completion. All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[27,28,29],"Healthy","Suboptimal Vitamin C Levels","Adequate Vitamin C Levels",[31,32,33,34,35,36,37],"Vitamin C","Ascorbic acid","Whole Blood Vitamin C","fatigue","immune function","Quality of Life","bioflavonoids","NOT_YET_RECRUITING","2026-06-10",{"date":41,"type":42},"2026-06-17","ACTUAL",{"date":44,"type":21},"2026-07",{"date":46,"type":21},"2026-12",{"name":48,"class":49},"Qualia Life Sciences","INDUSTRY",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":15,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":61,"targetDuration":4,"studyType":22,"phases":63,"briefSummary":64,"conditions":65,"keywords":67,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":4},"100635728","efficacy-of-qualia-testosterone-on-testosterone-levels-in-adult-males-100635728","NCT07556458","Efficacy of Qualia Testosterone+ on Testosterone Levels in Adult Males","The Efficacy of Qualia Testosterone+ on Testosterone Levels: A Randomized Triple-Armed Placebo-Controlled Parallel Study","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Male participants aged 28-65\n* A ≤500 ng\u002FdL Total Testosterone at baseline\n* Willing and able to visit a local blood draw facility for required blood sample collections\n* Live within 20 miles of a suitable blood draw facility\n* Willing to not consume any supplements containing Testosterone or botanicals known to impact hormones starting about 2 weeks prior to the baseline blood test and continuing through the intervention period.\n\nExclusion Criteria:\n\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, blood thinners, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent\n* Female\n* Have Hypogonadism\n* On Testosterone Replacement Therapy\n* Taking Gonadotropin-releasing hormone (GnRH) injections or gonadotropins (hCG or FSH)","MALE","28 Years","65 Years",{"count":62,"type":21},75,[24],"This is a randomized, double-blind, placebo-controlled, triple-arm, parallel-group study evaluating the efficacy and tolerability of two distinct Qualia Testosterone+ formulations, novel dietary supplements formulated to support endogenous testosterone, in adult males aged 28-65. Approximately 75 participants will be randomized equally to receive Qualia Testosterone+ Formula 1, Qualia Testosterone+ Formula 2, or a matched placebo (3 capsules once each morning) for 28 days. The primary outcome is between-group change in total testosterone from baseline to day 28. Secondary outcomes include changes in free (dialysis) testosterone, the Aging Male Symptoms Scale, the PROMIS Short Form v1.0 - Fatigue 10a, and safety and tolerability assessments. Blood samples will be collected in a clinical laboratory setting, while symptom and safety assessments will be completed electronically at home.",[66],"Low Testosterone Levels",[68,69,70],"Testosterone","Dietary Supplement","Male Vitality","2026-04-22",{"date":73,"type":42},"2026-04-29",{"date":75,"type":21},"2026-04-08",{"date":77,"type":21},"2026-06-03",{"name":48,"class":49},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":83,"acronym":4,"eligibilityCriteria":84,"healthyVolunteers":11,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":4,"studyType":22,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":4},"100620756","qualia-perimenopause-efficacy-and-tolerability-study-an-open-label-3-arm-trial-100620756","NCT07361757","Qualia Perimenopause Efficacy and Tolerability Study: An Open-label 3-Arm Trial","Inclusion criteria:\n\n1. Provide voluntary, written, informed consent to participate in the study\n2. Agree to provide a valid cell phone number and are willing to receive communications through text\n3. Can read and write English\n4. Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly\n5. Willing to complete questionnaires, records, and diaries associated with the study\n6. Healthy female participants ages 40-55 with menopause symptoms but not yet in menopause (period within last 12 months)\n7. MRS total score ≥ 5 (preference given to higher score)\n\nExclusion criteria:\n\n1. Women who are pregnant, breastfeeding, or planning to become pregnant or start breastfeeding during the trial\n2. Known food intolerances\u002Fallergy to any ingredients in the product\n3. Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n4. Having had a significant cardiovascular event in the past 6 months\n5. Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n6. On immunosuppressive therapy\n7. Having had surgery within the past 6 weeks or upcoming planned surgery in the next few months\n8. Adults lacking capacity to consent\n9. Post-menopause (≥12 consecutive months without a period)\n10. Taking medications: hormone replacement therapy; oral contraceptives; selective estrogen receptor modulators\u002Faromatase inhibitors (e.g., Tamoxifen); sedatives\u002Fanxiolytics; blood thinners; insulin","FEMALE","40 Years","55 Years",{"count":89,"type":21},120,[24],"This is an open-label, 3-arm clinical trial evaluating the short-term efficacy and tolerability of Qualia Perimenopause-a multi-ingredient dietary supplement formulated to support perimenopausal symptoms-in healthy women aged 40-55 who are symptomatic but not yet menopausal (menses within the past 12 months). Approximately 120 participants will be allocated across three parallel arms and will take 1 capsule once daily for 28 consecutive days. The primary outcome is between-group change from baseline to day 28 in menopause symptom burden measured by the total Menopause Rating Scale (MRS). Secondary outcomes include within- and between-group changes at days 14 and 28 in cognitive function (PROMIS Cognitive Function v2.0 - Short Form 8a), sleep disturbance (PROMIS), MRS subdomains (psychological, somato-vegetative, urogenital), overall MRS change, safety\u002Ftolerability (custom survey), and participant-reported product experience. All assessments are completed electronically at home at baseline, mid-intervention (day 14), and end-of-study (day 28), with a brief follow-up questionnaire; there are no in-person visits.",[93],"Peri-menopausal Women","2026-01-15",{"date":96,"type":42},"2026-01-23",{"date":98,"type":21},"2026-02-01",{"date":100,"type":21},"2026-04-30",{"name":48,"class":49},{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":106,"acronym":4,"eligibilityCriteria":107,"healthyVolunteers":15,"sex":16,"minAge":108,"maxAge":18,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":116,"lastUpdatePostDateStruct":117,"startDateStruct":119,"completionDateStruct":121,"leadSponsor":123,"locationsCount":50},"100610005","the-impact-of-qualia-gluthathione-on-blood-glutathione-levels-100610005","NCT07221955","The Impact of Qualia Gluthathione+ on Blood Glutathione Levels","Inclusion criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Healthy male and female participants aged 45-75 years\n* Willing to go to a local blood draw location for a Whole Blood Total Glutathione measurement (baseline and Day 20)\n* Willing to avoid starting new or stopping any existing dietary supplements throughout the study\n\nExclusion criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Adults lacking capacity to consent\n* Active Smokers\n* Diagnosed Diabetics","45 Years",{"count":110,"type":21},54,[24],"This is a randomized, double-blind, placebo-controlled, parallel-group, triple-armed, study evaluating the effects of two distinct Qualia Glutathione+ formulations on Whole Blood Glutathione levels in the blood of healthy adults aged 45-75 years. Approximately 18 participants will be randomized to one of three study arms: Qualia Glutathione+ version 1, Qualia Glutathione+ version 2, or placebo. Each participant will take two or three capsules of their assigned product once daily in the morning, with or without food, over a 20-day period. The primary outcome is the change in blood glutathione levels, assessed via in lab blood collection at baseline and study completion. Secondary endpoints include questionnaires measuring health-related quality of life, fatigue, and cognitive functioning (PROMIS Global Health-10, PROMIS Short Form v1.0 - Fatigue 10a, PROMIS Cognitive Function - Short Form 8a), evaluation of safety and tolerability, and an Overall Experience Questionnaire (Appendices 1, 4-7). All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[114,115],"Effects of Qualia Glutathione+ on Blood Glutathione Levels","Glutathione","2025-11-12",{"date":118,"type":42},"2025-11-14",{"date":120,"type":21},"2025-12-02",{"date":122,"type":21},"2026-01-25",{"name":48,"class":49},{"id":125,"slug":126,"hasResults":11,"nctId":127,"briefTitle":128,"officialTitle":129,"acronym":4,"eligibilityCriteria":130,"healthyVolunteers":15,"sex":16,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":134,"briefSummary":135,"conditions":136,"keywords":138,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":50},"100604977","impact-of-two-iron-formulations-on-iron-biomarkers-and-quality-of-life-100604977","NCT07156526","Impact of Two Iron Formulations on Iron Biomarkers and Quality of Life","Safety and Efficacy of Two Qualia Iron Formulations on Iron Biomarkers and Quality of Life: A Randomized, Double-Blind Pilot Study","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* If the participant responded \"Yes\" to ≥2 questions on the custom Iron Inadequacy Questionnaire. Preference will be given to participants with a higher score.\n* If a participant has the following:\n\nFerritin 30 ng\u002FmL (anything under 50 ng\u002FmL is considered suboptimal, but participants with 30 ng\u002FmL will be prioritized)\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, irritable bowel disease, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent\n* Individuals taking any of the following medications:\n\nAntacids Proton pump inhibitors (PPIs) Antipsychotics Antibiotics","18 Years",{"count":133,"type":21},40,[24],"This randomized, double-blind parallel pilot study will evaluate the safety and efficacy of two Qualia Iron formulations versus placebo in approximately 40 healthy adults (aged 18+) over a 56-day period. Approximately 40 participants will be randomized to three study arms: Qualia Iron Version 1, 2, (n=15 each) or a Placebo (n=10). Each participant will take one or two capsules once daily in the morning, with or without food. The supplementation regimen is a 5 days on, 2 days off protocol, and goes for 56 days (8 weeks). The primary outcomes of this study are to assess between-group changes in iron status biomarkers. Secondary outcomes include within-group changes in iron status biomarkers, safety and tolerability as measured by a custom Safety and Tolerability survey, and RAND SF-36 quality of life scores.",[137],"Iron Deficiencies",[139,140],"Iron supplementation","Iron deficiency","2025-08-27",{"date":143,"type":42},"2025-09-05",{"date":145,"type":21},"2025-09-10",{"date":147,"type":21},"2025-11-15",{"name":48,"class":49},{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":154,"acronym":4,"eligibilityCriteria":155,"healthyVolunteers":15,"sex":16,"minAge":156,"maxAge":18,"enrollmentInfo":157,"targetDuration":4,"studyType":22,"phases":159,"briefSummary":160,"conditions":161,"keywords":164,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":166,"lastUpdatePostDateStruct":167,"startDateStruct":169,"completionDateStruct":171,"leadSponsor":173,"locationsCount":50},"100603152","comparison-of-two-qualia-nad-formulations-on-intracellular-nad-levels-100603152","NCT07132801","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels","Comparison of Two Qualia NAD⁺ Formulations on Intracellular NAD⁺ Levels: A Randomized, Double-Blind, Placebo-Controlled Three-Arm Trial","Inclusion Criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nHealthy male and female participants aged 35-75 years Willing to self-administer the intracellular NAD⁺ finger-stick test at home (baseline and Day 28) Willing to avoid supplements, energy drinks\u002Fshots, or other products containing niacin, niacinamide, nicotinamide riboside, or NMN for ≥ 2 weeks before baseline and throughout the study\n\nExclusion Criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent","35 Years",{"count":158,"type":21},180,[24],"This is a randomized, double-blind, placebo-controlled, parallel-group study evaluating the effects of two distinct Qualia NAD⁺ formulations on intracellular NAD⁺ levels in healthy adults aged 35-75 years. Approximately 180 participants will be randomized to one of three study arms: Qualia NAD⁺ version 1, Qualia NAD⁺ version 2, or placebo. Each participant will take two capsules of their assigned product once daily in the morning, with or without food, over a 28-day period. The primary outcome is the change in intracellular NAD⁺ levels, assessed via at-home finger-stick blood collection at baseline and study completion. Secondary endpoints include changes in aging-related symptoms (AMFS scores), health-related quality of life (RAND SF-36), and evaluation of safety and tolerability. All assessments, including electronic questionnaires, are completed remotely without in-person visits.",[162,163],"NAD","NAD+ Levels in the Blood",[165,162],"NAD Supplementation","2025-08-13",{"date":168,"type":42},"2025-08-20",{"date":170,"type":21},"2025-10-13",{"date":172,"type":21},"2025-12-15",{"name":48,"class":49},{"id":175,"slug":176,"hasResults":11,"nctId":177,"briefTitle":178,"officialTitle":179,"acronym":4,"eligibilityCriteria":180,"healthyVolunteers":15,"sex":58,"minAge":59,"maxAge":60,"enrollmentInfo":181,"targetDuration":4,"studyType":22,"phases":183,"briefSummary":184,"conditions":185,"keywords":186,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":50},"100595115","effectiveness-of-qualia-testosterone-supplementation-on-testosterone-levels-100595115","NCT07028255","Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels","Effectiveness of Qualia Testosterone Supplementation on Testosterone Levels: A Randomized Double-Blind Parallel Trial","Inclusion criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text Can read and write English Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly Willing to complete questionnaires, records, and diaries associated with the study.\n\nMale participants aged 28-65 A score ≥27 on the Aging Males Symptom Scale Willing and able to visit a local blood draw facility for required blood sample collections Live within 20 miles of a suitable blood draw facility Willing to not consume any supplements containing Testosterone starting about 2 weeks prior to the baseline blood test test continuing through the intervention period.\n\nExclusion criteria:\n\nKnown food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent Have Hypogonadism",{"count":182,"type":21},60,[24],"This is a randomized, double-blind, placebo-controlled parallel trial designed to assess the efficacy of Qualia Testosterone, a novel dietary supplement, in adult males aged 28 to 65 experiencing symptoms associated with testosterone deficiency. Approximately 60 participants will be randomized to receive either Qualia Testosterone (2 capsules daily) or a matched placebo for 21 days, with dosing administered each morning. The study's primary outcomes are changes in total testosterone, free testosterone (via dialysis), and dihydrotestosterone levels from baseline to Week 3. Secondary outcomes include changes in Aging Male Symptoms Scale scores-encompassing psychological, somatic, and sexual domains-as well as safety and tolerability. Blood samples will be collected in a laboratory setting, while symptom and safety assessments will be completed electronically at home.",[68],[187,188],"testosterone supplementation","testosterone","2025-06-11",{"date":191,"type":42},"2025-06-19",{"date":193,"type":21},"2025-07-01",{"date":195,"type":21},"2025-10-01",{"name":48,"class":49},{"id":198,"slug":199,"hasResults":11,"nctId":200,"briefTitle":201,"officialTitle":202,"acronym":4,"eligibilityCriteria":203,"healthyVolunteers":15,"sex":16,"minAge":204,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":211,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":214,"lastUpdatePostDateStruct":215,"startDateStruct":217,"completionDateStruct":219,"leadSponsor":221,"locationsCount":50},"100591378","effectiveness-of-qualia-magnesium-supplementation-on-rbc-magnesium-levels-100591378","NCT06979648","Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels","Effectiveness of Qualia Magnesium+® Supplementation on RBC Magnesium Levels: A Randomized Double-Blind Parallel Trial","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text\n* Can read and write English\n* Willing to complete questionnaires, records, and diaries associated with the study.\n* Male and female participants aged 21 years and older\n* Willing and able to visit a local blood draw facility for required blood sample collections\n* Live within 20 miles of a suitable blood draw facility (such as Quest)\n* RBC Magnesium levels below 6.0 mg\u002FdL\n* Willing to not consume any supplements containing magnesium starting about 2 weeks prior to the baseline magnesium blood test and continuing through the intervention period.\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly with the exception of those containing magnesium\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent","21 Years",{"count":206,"type":21},100,[24],"This is a randomized, double-blind, placebo-controlled parallel trial designed to evaluate the effectiveness of Qualia Magnesium+® supplementation on red blood cell (RBC) magnesium levels in adults aged 21 and older. Approximately 100 participants with baseline RBC magnesium levels below 6.0 mg\u002FdL will be randomly assigned to receive either Qualia Magnesium+ or a placebo. Participants will take 2 capsules daily in the evening, with or without food, for a duration of 12 weeks. The primary outcome is the between-group change in RBC magnesium levels from baseline to Week 12. Secondary outcomes include assessments of sleep quality, perceived stress, magnesium status, and safety and tolerability. Data collection will occur through lab bloodwork and electronic questionnaires.",[210],"Magnesium Deficiency",[212,213],"Magnesium supplementation","magnesium","2025-05-13",{"date":216,"type":42},"2025-05-20",{"date":218,"type":21},"2025-05-21",{"date":220,"type":21},"2025-09-21",{"name":48,"class":49},{"id":223,"slug":224,"hasResults":11,"nctId":225,"briefTitle":226,"officialTitle":226,"acronym":4,"eligibilityCriteria":227,"healthyVolunteers":15,"sex":16,"minAge":108,"maxAge":228,"enrollmentInfo":229,"targetDuration":4,"studyType":22,"phases":230,"briefSummary":231,"conditions":232,"keywords":234,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":236,"lastUpdatePostDateStruct":237,"startDateStruct":239,"completionDateStruct":241,"leadSponsor":243,"locationsCount":50},"100589369","an-open-label-pilot-study-of-qualia-senolytic-supplementation-for-the-attenuation-of-systemic-inflammatory-cytokines-100589369","NCT06953518","An Open-Label Pilot Study of Qualia Senolytic Supplementation for the Attenuation of Systemic Inflammatory Cytokines","Inclusion Criteria:\n\n* Provide voluntary, written, informed consent to participate in the study\n* Agree to provide a valid cell phone number and are willing to receive communications through text.\n* Healthy adults 45 - 79 years of age Can read and write English\n* Willing to not begin taking any new supplements during the study and continue taking any supplements they are currently using regularly.\n* Willing to self-administer the fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives NHC access to the results of these tests.\n* Willing to complete questionnaires, records, and diaries associated with the study.\n\nExclusion Criteria:\n\n* Women who are pregnant, breastfeeding, or planning to become pregnant during the trial\n* Known food intolerances\u002Fallergy to any ingredients in the product\n* Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer\n* Having had a significant cardiovascular event in the past 6 months\n* Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines\n* On immunosuppressive therapy\n* Individuals who were deemed incompatible with the test protocol\n* Adults lacking capacity to consent","79 Years",{"count":133,"type":21},[24],"This open-label pilot study includes adults aged 45 to 79 residing in the United States. The study will last 7 days. Participants will provide blood samples via an at-home finger-prick kit at baseline and day 7 and complete electronic surveys on health indicators at baseline, and days 3 and 7. All procedures are conducted remotely, with no in-person visits, to collect real-world evidence.",[233],"Inflammation",[235],"Senolytic","2025-04-23",{"date":238,"type":42},"2025-05-01",{"date":240,"type":21},"2025-05-12",{"date":242,"type":21},"2025-05-18",{"name":48,"class":49},{"id":245,"slug":246,"hasResults":11,"nctId":247,"briefTitle":248,"officialTitle":249,"acronym":4,"eligibilityCriteria":250,"healthyVolunteers":15,"sex":16,"minAge":86,"maxAge":60,"enrollmentInfo":251,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":254,"conditions":255,"keywords":4,"overallStatus":256,"whyStopped":4,"lastUpdateSubmitDate":257,"lastUpdatePostDateStruct":258,"startDateStruct":260,"completionDateStruct":262,"leadSponsor":264,"locationsCount":50},"100554967","effectiveness-of-qualia-nad-supplementation-on-intracellular-nad-levels-100554967","NCT06505967","Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels","Effectiveness of Qualia NAD+ Supplementation on Intracellular NAD Levels: A Randomized Double-Blind Parallel Trial","Inclusion criteria:\n\nProvide voluntary, written, informed consent to participate in the study Agree to provide a valid cell phone number and are willing to receive communications through text.\n\nHealthy male and female participants between the ages of 40-65 years of age. Willingness to complete questionnaires, records, and diaries associated with the study.\n\nWilling to not consume any supplements, energy drinks\u002Fshots, or other products containing any form of supplemental vitamin B3 (e.g., niacin, niacinamide, nicotinamide ribosome, NMN) starting about 2 weeks prior to the baseline NAD fingerstick test and continuing through the intervention period.\n\nWilling to not begin taking any new supplements during the study period, and to continue taking any supplements they are currently using regularly (with the exception of vitamin B3 containing supplements).\n\nWillingness to self-administer the intracellular NAD fingerstick test kit at home for both a baseline and post-intervention blood sample, and to complete a release form that gives researchers access to the results of these tests.\n\nExclusion criteria:\n\nWomen who are pregnant, breastfeeding, or planning to become pregnant during the trial Known food intolerances\u002Fallergy to any ingredients in the product Having any of the following conditions: Psychiatric conditions, neurologic disorders, endocrine disorders, cancer Having had a significant cardiovascular event in the past 6 months Taking MAO inhibitors, SSRIs, or any other psychiatric or neurological medicines On immunosuppressive therapy Individuals who were deemed incompatible with the test protocol Adults lacking capacity to consent",{"count":252,"type":21},200,[24],"The goal of this clinical trial is to determine if Qualia NAD+ effectively increases NAD+ levels in the blood and to evaluate its safety.\n\nResearchers will compare Qualia NAD+ to a placebo (a look-alike substance that contains no active drug) to assess its efficacy in increasing NAD+ levels in the blood.\n\nParticipants will:\n\nTake Qualia NAD+ or a placebo every day for 4 weeks. Undergo blood tests before and after the trial.",[163],"RECRUITING","2024-07-11",{"date":259,"type":42},"2024-07-17",{"date":261,"type":42},"2024-06-10",{"date":263,"type":21},"2024-09-09",{"name":48,"class":49},""]